Year: 2013
Type: review
Abstract: Cancer chemoprevention involves the chronic administration of a synthetic, natural or biological agent to reduce or delay the occurrence of malignancy. The potential value of this approach has been demonstrated with trials in breast, prostate and colon cancer. The paradigm for developing new chemopreventive agents has changed markedly in the last decade and now involves extensive preclinical mechanistic evaluation of agents before clinical trials are instituted and a focus on defining biomarkers of activity that can be used as early predictors of efficacy. This review will summarise the current status of the field of chemoprevention and highlight potential new developments.
Source: British Journal of Cancer
DOI: 10.1038/bjc.2013.280
Authors: W P Steward, K Brown
Institutions: University of Leicester, Leicester Royal Infirmary
Language: English
Subfield: Pharmacology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,190
Funder: Cancer Research UK
Award: G768853933
OpenAlex ID: W2045617306